Celltrion's blood cancer treatment, Truxima (rituximab), has strengthened its market dominance in the United States by maintaining the number one prescription share for four consecutive months.
According to IQVIA, a pharmaceutical market research firm, Truxima recorded a 38.6% market share in May, continuing its lead since February. This marks a 2.8 percentage point increase from when it first achieved the top position in February, widening the gap with competing products, including original medications.
Truxima is the first biosimilar from South Korea to secure the top market share in the U.S., earning recognition for gaining an edge over global pharmaceutical giants.
The growth trend is expected to continue. Earlier this month, Truxima became the first rituximab biosimilar to receive 'interchangeability' status from the U.S. Food and Drug Administration (FDA). This allows pharmacies to substitute it for the original drug, potentially accelerating its penetration into the approximately 20% market share currently held by the original product.
Other product lines are also showing stable growth in the U.S. The autoimmune disease treatment, Inflectra, maintained a leading position with a 30.4% market share during the same period, while Stexima (13.3%), Vegzelma (10.6%), and Uplizna (8.1%) are also expanding their presence in the market.
Celltrion plans to sustain its growth by launching follow-up products in the second half of the year. Its U.S. subsidiary is preparing to release subcutaneous formulations of Abtozuma (tosilizumab) and Omniclo (omalizumab), aiming to establish a foothold in the market using its existing pharmacy benefit manager (PBM) network.
A Celltrion representative stated, "Based on the sales performance of our key products, we will ensure that our upcoming launches can quickly capture the U.S. market."
Meanwhile, Celltrion continues to report strong performance due to the expansion of high-margin new product sales and improvements in cost structure. The company recorded preliminary second-quarter revenues of 1.3 trillion won and an operating profit of 430 billion won, achieving the highest quarterly results in its history. Compared to the same period last year, revenues increased by 35.2%, and operating profit rose by 77.3%.
The operating profit margin also improved from about 25% in the second quarter of last year to approximately 33% in the second quarter of this year. With increased sales of existing flagship products alongside new products like Remsima SC, Uplizna, and Stexima, the share of new products in total revenue has surpassed 60%.
According to IQVIA, a pharmaceutical market research firm, Truxima recorded a 38.6% market share in May, continuing its lead since February. This marks a 2.8 percentage point increase from when it first achieved the top position in February, widening the gap with competing products, including original medications.
Truxima is the first biosimilar from South Korea to secure the top market share in the U.S., earning recognition for gaining an edge over global pharmaceutical giants.
The growth trend is expected to continue. Earlier this month, Truxima became the first rituximab biosimilar to receive 'interchangeability' status from the U.S. Food and Drug Administration (FDA). This allows pharmacies to substitute it for the original drug, potentially accelerating its penetration into the approximately 20% market share currently held by the original product.
Other product lines are also showing stable growth in the U.S. The autoimmune disease treatment, Inflectra, maintained a leading position with a 30.4% market share during the same period, while Stexima (13.3%), Vegzelma (10.6%), and Uplizna (8.1%) are also expanding their presence in the market.
Celltrion plans to sustain its growth by launching follow-up products in the second half of the year. Its U.S. subsidiary is preparing to release subcutaneous formulations of Abtozuma (tosilizumab) and Omniclo (omalizumab), aiming to establish a foothold in the market using its existing pharmacy benefit manager (PBM) network.
A Celltrion representative stated, "Based on the sales performance of our key products, we will ensure that our upcoming launches can quickly capture the U.S. market."
Meanwhile, Celltrion continues to report strong performance due to the expansion of high-margin new product sales and improvements in cost structure. The company recorded preliminary second-quarter revenues of 1.3 trillion won and an operating profit of 430 billion won, achieving the highest quarterly results in its history. Compared to the same period last year, revenues increased by 35.2%, and operating profit rose by 77.3%.
The operating profit margin also improved from about 25% in the second quarter of last year to approximately 33% in the second quarter of this year. With increased sales of existing flagship products alongside new products like Remsima SC, Uplizna, and Stexima, the share of new products in total revenue has surpassed 60%.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.